ZYNLONTA Phase 3 trial meets primary endpoint in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ADC Therapeutics SA)

NYSE: ADCT−55.84% 24h move
Price before$3.08Jun 3, 2026, 4:00 PM ET
First trade after$1.95Jun 3, 2026, 4:18 PM ET
24h later$1.36Jun 4, 2026, 4:16 PM ET

Complete Announced during: After hours · announced Wed 4:17p ET (after hours); before = Wed close; first trade Wed 4:18p ET; time = SEC 8-K acceptance

ADC Therapeutics SA (NYSE: ADCT) reported topline results from a Phase 3 trial of ZYNLONTA in relapsed or refractory diffuse large B-Cell lymphoma on June 3, 2026. The company said the trial met its primary endpoint. ClinicalTrials.gov lists 440 enrolled participants (NCT04384484).

Trial details

Drug
ZYNLONTAType Drug Route intravenous
Treats
Studied as a treatment for relapsed or refractory diffuse large B-Cell lymphoma (registry condition: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma).Conditions Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Patients
440 patients (actual enrollment)3 arms · 144 sites in 21 countries
Phase
Phase 3
Design
Randomized, open-label, parallel-group
Primary endpoint
Progression-free Survival (PFS) (Up to 4 years)
Key secondary endpoints
  • Overall Survival (OS)
  • Overall Response Rate (ORR)
  • Complete Response Rate (CRR)
Result
Met endpointThe study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx.
Safety
Overall, treatment emergent adverse event (TEAE) rates were similar between arms.
Sponsor
ADC Therapeutics SA NYSE: ADCT
Dates
Study start Sep 16, 2020Primary completion Mar 31, 2026Announced Jun 3, 2026, 4:17 PM ET (SEC 8-K filing time)
Trial ID
NCT04384484 ClinicalTrials.gov

About this trial

This randomized, open-label, parallel-group Phase 3 trial (NCT04384484) tested ZYNLONTA in Relapsed Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma. Studied as a treatment for relapsed or refractory diffuse large B-Cell lymphoma (registry condition: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma). It enrolled 440 patients across 3 arms at 144 sites in 21 countries. The primary endpoint was Progression-free Survival (PFS) (Up to 4 years). ADC Therapeutics SA reported that the trial met its primary endpoint. The study started on Sep 16, 2020 and reached primary completion on Mar 31, 2026.

Sources

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.